Search Results 321-330 of 18829 for prostate cancer
Clinical Trials · A Study to Compare Docetaxel/Prednisone to Docetaxel/Prednisone Combined with OGX-011 in Men with Prostate Cancer · More about research at Mayo ...
About this study. This is a single patient study of an investigational drug CPI-613 for treatment of metastatic prostate cancer. Participation eligibility.
The purpose of this study is to determine the safety of the NanoKnife treatment in prostate cancer tissue when used in a low and intermediate risk patient ...
A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate ...
... prostate cancer. Prostate Cancer Prostatic Dis. 2022 Sep; 25 (3):479-483 Epub 2021 July 22. View PubMed; Nafissi NN, Kosiorek HE, Butterfield RJ, Moore C, Ho ...
Oligorecurrent prostate cancer treated with metastases-directed therapy or standard of care: a single-center experience. Prostate Cancer Prostatic Dis. 2021 ...
Prostate cancer / exercise and the heart / headaches. 00:00. |. Prostate cancer / exercise and the heart / headaches. Feb. 22, 2020. Show Coverart. Donate. + ...
Unfortunately, most men in this situation will go on to develop metastatic castration-resistant prostate cancer (mCRPC) and require secondary systemic therapy.
Topics include bone health, nutrition, PSA monitoring, erectile dysfunction and incontinence. What to Expect from Prostate Cancer Treatment. Bradley Leibovich, ...
... prostate cancer (mCRPC) who have previously been treated with one, and only one, NHT for their prostate cancer disease. Participation eligibility.
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Their crucial work saves lives every day. Let Mayo Clinic researchers know they’re appreciated with a quick message.